| Study | Population | Intervention | Comparison | Details of inadequate response/treatment resistance | Comments |
|---|---|---|---|---|---|
|
RCT 16 countries |
N=305 Mean age (years): NR Gender (% female): NR Ethnicity (% BME): NR Baseline severity: NR (more severe) | Fluoxetine 25 or 50mg/day + Olanzapine 6 or 12mg/day | Olanzapine 6 or 12mg/day | TRD: Inadequate response to a SSRI after at least 6 weeks at a therapeutic dose at entry into the trial and inadequate response (<30% improvement in MADRS total score) to an open-label, 7-week lead-in phase of venlafaxine (75–375 mg/day according to the investigator’s clinical judgment) |
Treatment length (weeks): 12 Outcomes:
|
|
RCT US & Canada |
N=290 Mean age (years): 43.0 Gender (% female): 66 Ethnicity (% BME): 13 Baseline severity: MADRS 28.45 (more severe) | Fluoxetine 25-50mg/day + Olanzapine 6-12mg/day | Olanzapine 6-12mg/day | TRD: History of at least 1 failure to respond to SSRI after at least 4 weeks at a therapeutic dose, and failure to respond (<30% improvement on MADRS) to nortriptyline (25-175mg/day; mean modal dose 104.6mg/day) during a 7-week open-label treatment phase |
Treatment length (weeks): 8 Outcomes:
|
BME: black and minority ethnic; MADRS: Montgomery-Asberg depression rating scale; NR: not reported; RCT: randomised controlled trial; SSRI: selective serotonin reuptake inhibitor; TRD: treatment-resistant depression
From: Further-line treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.